Trevena, Inc. (NASDAQ:TRVN)

CAPS Rating: 5 out of 5

TRVN News and Commentary


How do you think TRVN will perform against the market?

Add Stock to CAPS Watchlist

All Players

35 Outperform
1 Underperform

All-Star Players

5 Outperform
1 Underperform

Wall Street

0 Outperform
0 Underperform

Top TRVN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

IBDvalueinvestin (98.36)
Submitted March 16, 2015

RA Capital - Peter Kolchinsky a Ph.D in Virology from Harvard has bought millions of shares within the last qtr. His track record suggests that TRVN will be a big winner.RA Capital posting third quarter returns of 51.5% and 1-year returns of… More

TSIF (99.97)
Submitted September 01, 2015

Trevena has some solid followers, but the froth after the Phase 2 data is excessive at this point. Cash burn high, investment "raise" needed before Phase III gets much traction. Well respected Barron's suggests target $20, so this one may get a bit… More


TRVN Summary

Fools bullish on TRVN are also bullish on:

Fools bearish on TRVN are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about TRVN.


Member Avatar bkinvest (70.68) Submitted: 11/3/2016 3:25:43 PM : Outperform Start Price: $3.88 TRVN Score: -87.43

Good entry


Member Avatar CM0330 (< 20) Submitted: 7/18/2016 10:34:44 PM : Outperform Start Price: $6.67 TRVN Score: -101.22

TRVN has the chance to revolutionize pain management, and how doctors administer medicine to deal with recovery for surgical procedures. WIth preliminary data from thier test trials looking strong, I look for the stock to break out in the low teens by early 2017, and potentially take off from there on once more positive data has been obtained.


Member Avatar shanelofgren (< 20) Submitted: 6/21/2016 3:43:40 PM : Outperform Start Price: $6.08 TRVN Score: -103.22

I think that they have very large effect size, highly robust data on their lead drug for pain. I think that their Ph2 is very good because the endpoints they chose match the ones the FDA will be looking for from the Ph3.

I think that there would be a very big market for a pain drug with an improved therapeutic index, though I haven't done any formal valuation of the lead asset compared with the company's cap - cash to support this. Just a feeling that the valuation is favorable.

Finally, their preclinical work is impressive and their earlier stage assets and the platform itself also feel quite valuable. Though again, no formal analysis there.

Overall, a positive feeling based mainly on reading their posters. Not ready to put real money into it, but like it enough to kick off CAPS round 2 (round 3?) with it.


Find the members with the highest scoring picks in TRVN.

Score Leader


anchak (99.91) Score: +122.40

The Score Leader is the player with the highest score across all their picks in TRVN.

Member Name Member
Call Time
Score Commentary
anchak 99.91 2/22/2016 Underperform NS $9.30 -81.89% +40.51% +122.40 0 Comment
Bigsef77 70.29 1/29/2018 Outperform 3M $1.77 -4.80% -4.23% -0.58 0 Comment
sunvestor7 44.54 10/17/2017 Outperform 5Y $1.85 -8.92% +6.92% -15.84 0 Comment
unikazi 71.24 9/15/2017 Outperform 5Y $2.52 -33.00% +9.65% -42.65 0 Comment
manirg < 20 7/31/2017 Outperform 5Y $2.61 -35.44% +10.67% -46.11 0 Comment
Bigeric98 99.96 3/30/2017 Outperform 1Y $3.74 -54.95% +15.68% -70.63 0 Comment
dancon7 48.94 3/3/2017 Outperform 3Y $4.13 -59.20% +14.67% -73.87 0 Comment
bkinvest 70.68 11/3/2016 Outperform 5Y $3.88 -56.57% +30.86% -87.43 2 Comments
Minion13 50.39 12/27/2016 Outperform 3M $6.05 -72.15% +20.83% -92.98 0 Comment
DoubleBagel 37.24 1/23/2017 Outperform 5Y $6.46 -73.92% +20.95% -94.87 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for TRVN.

Featured Broker Partners